四环医药(00460.HK)旗下中国生物制药公司轩竹生物-B(02575.HK)10月6日至10月10日招股。截至周三 （8日）晚上10时多，轩竹生物获券商借出至少858亿港元孖展，较下午的350亿港元增1.5倍；以公开发 售起初集资额7811万港元计，超额认购1097.5倍。轩竹生物每手500股，一手入场费为5858.5港元，轩竹 生物预期将于10月15日挂牌买卖，中金公司为独家保荐人。 ...

Core Viewpoint - Xuan Bamboo Biotech-B (02575.HK) is set to launch its global offering from October 6 to October 10, 2025, with a proposed share price of HKD 11.6 per share, aiming to raise funds for its innovative drug development in oncology and other fields [2] Group 1: Company Overview - Xuan Bamboo Biotech is one of the few high-tech biopharmaceutical companies in China that possesses capabilities in the development, industrialization, and commercialization of both small molecule drugs and large molecule biologics [2] - The company is focused on innovative drug development in areas such as oncology, digestive diseases, and NASH, with over ten drug assets currently under active development [2] Group 2: Financial Performance - The company reported revenues of RMB 29 million, RMB 300.9 million, RMB 65.1 million, and RMB 25.6 million for the years 2023, 2024, and the three months ending March 31, 2025, respectively, with all income derived from the commercialization of its drug KBP-3571 [2] - Research and development expenditures for the years 2023, 2024, and the three months ending March 31, 2025, were RMB 239.06 million, RMB 186.40 million, RMB 38.89 million, and RMB 53.04 million, respectively [3] - The company is currently operating at a loss, with net losses of RMB 300.6 million, RMB 556.4 million, RMB 111.0 million, and RMB 110.9 million for the years 2023, 2024, and the six months ending June 30, 2025, primarily due to the early stage of its commercialization strategy and operational expenses incurred during the reporting periods [3]

Market Overview - The Hong Kong stock market opened slightly lower on October 6, with the Hang Seng Index at 27,003 points, down 137 points, a decline of 0.50% [1] - The Hang Seng Technology Index reported 6,548.80 points, down 74.05 points, a decrease of 1.12% [4] New IPO - Xuan Bamboo Biotechnology-B (02575.HK) is conducting an IPO from October 6 to October 10, planning to globally offer 67.335 million shares, with 10% allocated for Hong Kong and 90% for international sales, plus a 15% over-allotment option, at a price of HKD 11.6 per share [3] - The stock is expected to start trading on the Hong Kong Stock Exchange on October 15 [3] - Xuan Bamboo is an innovative Chinese biopharmaceutical company with over ten drug assets in active development, targeting digestive diseases, tumors, and non-alcoholic fatty liver disease (NASH) [3] Sector Performance - Technology stocks generally declined, with NetEase opening down over 2% but later recovering; Bilibili, Lenovo, Alibaba, JD.com, and Baidu all fell over 1%, while Tencent saw a rise of over 1% [3] - Gold stocks experienced gains, with China Silver Group up over 10% and Zifeng Gold up over 5% [3] - Semiconductor stocks were active, with Hongguang Semiconductor rising over 1% [3] - Automotive stocks weakened, with Xpeng Motors down over 4% [3] Market Sentiment and Forecast - According to Industrial Securities, the current Hong Kong market is driven by three favorable factors: rising policy expectations, bottoming earnings recovery, and a loose liquidity environment, which may enhance market risk appetite [5] - The Federal Reserve has entered a rate-cutting cycle, with expectations for further cuts in October, creating a more favorable external environment for Hong Kong stocks [5] - Guosen Securities noted that the Fed's dovish stance improves overseas liquidity, and the unusual rise in Hong Kong stocks amid earnings downgrades in August and September indicates a systematic change in risk premium, opening up further upside potential for the market [5] - The weighted risk premium assessment has led to an upward revision of the 2025 Hang Seng Index target to 29,000 points [5]

（一家於中華人民共和國註冊成立的股份有限公司） 重要提示 重要提示： 閣下如對本招股章程的任何內容有任何疑問，應徵詢獨立專業意見。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 全球發售 獨家保薦人及保薦人兼整體協調人 聯席整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本招股章程的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明 確表示概不就因本招股章程全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本招股章程，連同本招股章程「附錄七－送呈公司註冊處處長及展示文件」所述的文件，已按照香港法例第32章公司（清盤及雜項條文）條例第342C條的規定由 香港公司註冊處處長登記。香港證券及期貨事務監察委員會及香港公司註冊處處長對本招股章程或上述任何其他文件的內容概不負責。 發售價將為11.60港元。香港發售股份申請人於申請時須支付發售價每股香港發售股份11.60港元，連同1.0%經紀佣金、0.0027%證監會交易徵費、0.00015%會 財局交易徵費及0 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 除非本公告另有界定，否則本公告所用詞彙與軒竹生物科技股份有限公司（「本公司」）日期為 2025年10月6日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 潛在投資者在決定是否投資發售股份前，應細閱招股章程以了解下文所述有關全球發售的詳細 資料。投資者應僅依賴招股章程所載資料作出有關發售股份的任何投資決定。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區）發佈、刊 發、派發。本公告並不構成或組成在美國境內或於任何其他司法權區購買或認購證券的任何要 約或招攬的一部分。本公告所述證券並無亦不會根據1933年美國證券法（經不時修訂）（「美國 證券法」）或美國任何州或其他司法權區的證券法登記。該等證券不得在美國境內提呈發售、出 售、質押或以其他方式轉 ...